Filing Details

 

 

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

SCHEDULE 13G/A

Under the Securities Exchange Act of 1934

(Amendment No. 1)*

 

 

Kura Oncology, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

50127T 109

(CUSIP Number)

December 31, 2016

(Date of Event Which Requires Filing of this Statement)

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

☐

Rule 13d-1(b)

 

☐

Rule 13d-1(c)

 

☒

Rule 13d-1(d)

 

*	The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

---

CUSIP No. 50127T 109		13G		Page 2 of 5 Pages

 

1.		Names of Reporting Persons   Troy Edward Wilson
2.		Check the Appropriate Box if a Member of a Group (see instructions)   (a)  ☐ (b)  ☐
3.		SEC USE ONLY
4.		Citizenship or Place of Organization   United States
Number of Shares Beneficially Owned by Each Reporting Person With:				5.		Sole Voting Power
				6.		Shared Voting Power   2,181,4961
				7.		Sole Dispositive Power
				8.		Shared Dispositive Power   2,181,4961
9.		Aggregate Amount Beneficially Owned by Each Reporting Person   2,181,4961
10.		Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)        ☐
11.		Percent of Class Represented by Amount in Row 9   10.2%
12.		Type of Reporting Person (see instructions)   IN

 

 

1	Includes 38,769 shares subject to options exercisable within 60 days of 12/31/16.

---

CUSIP No. 50127T 109		13G		Page 3 of 5 Pages

 

Item 1(a).		Name of Issuer: Kura Oncology, Inc.
Item 1(b).		Address of Issuers Principal Executive Offices: 11119 N Torrey Pines Rd Ste 125, La Jolla, CA 92037.
Item 2(a).		Name of Person Filing: Troy Edward Wilson
Item 2(b).		Address of Principal Business Office or, if none, Residence: 11119 N Torrey Pines Rd Ste 125, La Jolla, CA 92037
Item 2(c).		Citizenship: United States
Item 2(d).		Title of Class of Securities: Common Stock
Item 2(e).		CUSIP Number: 50127T 109
Item 3.		If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:
(a)		☐		Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
(b)		☐		Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)		☐		Insurance company as defined in section 3(a)19) of the Act (15 U.S.C. 78c);
(d)		☐		Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)		☐		An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
(f)		☐		An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
(g)		☐		A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
(h)		☐		A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)		☐		A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)		☐		A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
(k)		☐		Group, in accordance with §240.13d-1(b)(1)(ii)(K).
		If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____

---

CUSIP No. 50127T 109		13G		Page 4 of 5 Pages

 

Item 4.		Ownership
		Amount Beneficially Owned: 2,181,496 shares of Common Stock. This amount includes (a) 38,769 shares subject to options exercisable within 60 days of December 31, 2016, (b) 1,735,991 shares of restricted common stock and common stock owned by Red Fish Blue Fish Revocable Trust, dated December 31, 2012, 729,167 shares of which are subject to a right of repurchase as of December 31, 2016, and (c) 406,736 shares of common stock owned by Araxes Pharma LLC, of which Dr. Wilson is the sole Manager.
(a)		Percent of Class: 10.2%
(b)		Number of shares as to which the person has:
		(i)		Sole power to vote or to direct the vote:  ___________
		(ii)		Shared power to vote or to direct the vote     2,181,496
		(iii)		Sole power to dispose or to direct the disposition of:  ___________
		(iv)		Shared power to dispose or to direct the disposition of     2,181,496
Item 5.		Ownership of 5 Percent or Less of a Class
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following  ☐.
Item 6.		Ownership of More than 5 Percent on Behalf of Another Person
Not Applicable
Item 7.		Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.
Not Applicable
Item 8.		Identification and Classification of Members of the Group
Not Applicable
Item 9.		Notice of Dissolution of a Group
Not Applicable

---

CUSIP No. 50127T 109		13G		Page 5 of 5 Pages

 

Item 10.		Certification
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Date: February 3, 2017				/S/ TROY EDWARD WILSON
				Troy Edward Wilson
The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representatives authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.
Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties for whom copies are to be sent.
Attention:		Intentional misstatements or omissions of fact constitute Federal criminal violations
		(See 18 U.S.C. 1001)